(Q44733664)

English

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

chronic myeloid leukemia

0 references

Alessandro Gozzetti

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Elisabetta Abruzzese

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Mario Tiribelli

7

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Gianantonio Rosti

13

object named as

Gianantonio Rosti

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Fausto Castagnetti

5

object named as

Fausto Castagnetti

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Massimo Breccia

8

object named as

Massimo Breccia

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Antonella Gozzini

12

object named as

Antonella Gozzini

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

15

object named as

Monica Bocchia

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Claudia Baratè

11

object named as

Claudia Baratè

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Marzia Salvucci

9

object named as

Marzia Salvucci

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1

object named as

Marzia Defina

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

author name string

Micaela Ippoliti

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Rosaria Crupi

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Francesco Lauria

14

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

0 references

publication date

19 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

118

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

5265-5269

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

21 January 2018

CD34+AC133+ Cells Isolated from Cord Blood are Highly Enriched in Long‐Term Culture‐Initiating Cells, NOD/SCID‐Repopulating Cells and Dendritic Cell Progenitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27506

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27506

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44733664&oldid=2035573837"